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Alternative oxidasent bacteria, we screened the Kitasato Institute for Life Sciences Chemical Library
with bacterial quinol oxidase, which does not exist in the mitochondrial respiratory chain. We identiﬁed ﬁve
prenylphenols, LL-Z1272β, γ, δ, ɛ and ζ, as new inhibitors for the Escherichia coli cytochrome bd. We found that
these compounds also inhibited the E. coli bo-type ubiquinol oxidase and trypanosome alternative oxidase,
although these three oxidases are structurally unrelated. LL-Z1272β and ɛ (dechlorinated derivatives) were
more active against cytochrome bdwhile LL-Z1272γ, δ, and ζ (chlorinated derivatives) were potent inhibitors
of cytochrome bo and trypanosome alternative oxidase. Thus prenylphenols are useful for the selective
inhibition of quinol oxidases and for understanding the molecular mechanisms of respiratory quinol oxidases
as a probe for the quinol oxidation site. Since quinol oxidases are absent from mammalian mitochondria, LL-
Z1272β and δ, which are less toxic to human cells, could be used as lead compounds for development of novel
chemotherapeutic agents against pathogenic bacteria and African trypanosomiasis.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe emergence of antibiotic-resistant strains of major pathogenic
bacteria such as Staphylococcus aureus is an increasingly serious public
health concern [1]. To evade bacterial drug-resistance mechanisms,
new effective chemotherapeutic agents, which have novel mechan-
isms of action as well as different cellular targets compared with
conventional antibiotics, need to be developed [2].
Cytochromes bo (CyoABCD) and bd (CydAB) are two terminal
quinol oxidases of the aerobic respiratory chain in Escherichia coli and
many other bacteria [3,4 for reviews]. Although they are structurally
unrelated, both generate proton-motive force through the oxidation of
quinols coupled to dioxygen reduction. Cytochrome bo is a proton-
pumping heme–copper terminal oxidases and is predominantly
expressed under highly aerated growth conditions. In contrast,
cytochrome bd is a predominant terminal oxidase under microaer-
ophilic growth conditions and performs a variety of physiological
functions such as microaerophilic respiration and protection against
oxygen stress. Further, cytochrome bd and its variant cyanide-
insensitive oxidase (CioAB) play a key role in survival and adaptation
of pathogenic bacteria that encounter host environments where
dioxygen is progressively limited [5–9].
In long slender bloodstream forms of the parasitic protist Trypano-
soma brucei, which causes sleeping sickness in human and nagana in81 3 5841 3444.
l rights reserved.livestock, mitochondrial respiratory Complexes III and IV are down-
regulated and alternative quinol oxidase (AOX) serves as a terminal
oxidase [10,11]. AOX is a di-iron family protein bound to the matrix side
of the innermembrane and cannot generate the proton-motive force. All
three quinol oxidases have no counterparts in mammalian mitochon-
dria, thus they are potential targets for novel antimicrobial chemother-
apeutics. In fact, we previously identiﬁed ascofuranone (AF), a
prenylphenol isolated from a phytopathogenic fungus Ascochyta viciae
[12], as a potent inhibitor for the growth of T. brucei and trypanosome
AOX (noncompetitive inhibition with IC50 of 2 nM) [13,14].
By screening of hundreds of natural antibiotics in the Kitasato
Institute for Life Sciences Chemical Library [15] with the E. coli
cytochrome bd, we found that LL-Z1272γ has potent inhibititory activity.
We extended our screening to related compounds and found that
antibiotics LL-Z1272β, γ, δ, ɛ and ζ (Fig. 1), prenylphenols isolated from
the fungus Verticillum sp. FO-2787 [16], are a unique set of natural
compounds that can discriminate and inhibit alternative respiratory
quinol oxidases. Thus, antibiotics LL-Z1272 are useful probes for
understanding of molecular mechanisms of quinol oxidases and we
hope that ourﬁndings contribute to the development of newantibiotics.
2. Materials and methods
2.1. Isolation or source of antibiotics and inhibitors
LL-Z1272β, γ, δ, ɛ and ζ were isolated from the cultured
mycelium Verticillum sp. FO-2787 [16]. Antibiotics LL-Z1272α, β, γ,
Fig. 1. Structures of antibiotics LL-Z1272 and related natural compounds.
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Fusarium sp. as inhibitors for the growth of the protist Tetrahymena
pyriformis [17]. Ilicicolin A, B, D, C, and F isolated from the fungus
Cylindrocladium ilicicola [18] are also identical to LL-Z1272α, β, γ,
δ, and ζ, respectively [19]. AF and piericidin A were kind gifts from
Drs. Masaichi Yamamoto (aRigen Pharmaceuticals. Inc.) and Shigeo
Yoshida (Institute of Physical and Chemical Research), respectively.
Synthesis of aurachin C 1-10 was described previously [20].
Antimycin A1 and 2-heptyl-4-hydroxyquinoline N-oxide (HQNO)
were purchased from Sigma.
2.2. Preparation of cytoplasmic membrane vesicles and puriﬁcation of
cytochrome bo
Cytochrome bd-overproduced membranes were isolated from E.
coli ST4683/pNG2 (Δcyo Δcyd/cyd+ TetR), which can overproduce bd-
type quinol oxidase as the sole terminal oxidase [21]. Heme d content
was 2.1±0.1 nmol/mg protein (i.e. approximately 20% of membrane
proteins). Cytochrome bo-type quinol oxidase was puriﬁed from
cytoplasmic membranes of E. coli GO103/pHN3795-1 (cyo+ Δcyd/cyo+
AmpR), as described previously [22]. Trypanosome AOX-overproduced
membranes were isolated from E. coli FN102 (BL21 (DE3) ΔhemA)/
pTvAOX, which can express Trypanosoma vivax AOX as the sole
functional quinol oxidase [23]. The expression level of AOX was
estimated to be ∼5% of membrane proteins by SDS-polyacrylamide gel
electrophoresis.
2.3. Quinol oxidase assay
The activity of the E. coli quinol oxidases was determined at
25 °C with a V-660 double monochromatic spectrophotometer
(JASCO, Tokyo, Japan) with data acquisition at 0.05 s. The reaction
mixture (1 ml) contained 50 mM potassium phosphate (pH 6.5),
and 0.02% Tween 20 (protein grade, Calbiochem) [24]. Enzyme
concentrations were 2.4 nM for cytochrome bd and 2 nM for
cytochrome bo. Reactions were started by addition of ubiquinol-1
(Q1H2) at a ﬁnal concentration of 100 μM, and the activity was
calculated by using a molar extinction coefﬁcient of 12,300 at
278 nm. The activity of T. vivax AOX was measured in 50 mMTris–HCl (pH 7.4)–0.1% sucrose monolaurate (Mitsubishi-Kagaku
Foods Co., Tokyo, Japan). Enzyme kinetics were analyzed based on
the modiﬁed ping-pong bi-bi mechanism for cytochrome bd [21]
or the Michaelis–Menten mechanism for cytochrome bo and T.
vivax AOX, by using KaleidaGraph ver. 4.0 (Synergy Software,
Reading, PA).
2.4. Dose–response analysis
Duplicate assays were performed at each concentration with two
independent preparations of membranes. Dose–response data were
analyzed by the nonlinear regression curve-ﬁtting with KaleidaGraph
ver. 4.0 as described previously [24]. IC50 values in the presence of
100 μM Q1H2 were estimated by using the equation for the relative
residual activity; v=1/(1+([Inhibitor] / IC50)n) where n is the Hill
coefﬁcient [24].
3. Results
3.1. Analysis of inhibition of cytochrome bd by antibiotics LL-Z1272
In the course of our screening for inhibitors against the E. coli
cytochrome bd, we identiﬁed LL-Z1272γ as an antibiotic that
suppressed the Q1H2 oxidation by the cytochrome bd-overproduced
membranes (84% inhibition at 5 μg/ml) greater than antimycin A
(50%), a non-competitive inhibitor of cytochrome bd [25]. We
extended our screening with antibiotics LL-Z1272β, γ, δ, ɛ and ζ,
prenylphenols isolated from Verticillum sp. FO-2787 [16], and found
that LL-Z1272β and ɛ were more potent inhibitors for cytochrome bd.
These compounds do not have a chlorine atom at position 5 of the
phenol ring (Fig. 1), and the cyclohexanone ring of LL-Z1272ɛ slightly
increased the binding afﬁnity to cytochrome bd (Table 1). The 50%
inhibitory concentrations (IC50) for LL-Z1272β and ɛ (dechlorinated
derivatives) were determined to be 2.1 and 1.1 μM (average values of
two independent preparations), respectively, and are one-order of
magnitude smaller than those of LL-Z1272γ, δ and ζ (chlorinated
derivatives) (Table 1). The IC50 values for known inhibitors for
cytochrome bd [20,25–27] are 10 μM for piericidin A, 5 μM for
antimycin A, 1 μM for HQNO, and 8.3 nM for aurachin C 1–10.
Table 1
Summary on IC50 values of quinol oxidase inhibitors for the E. coli cytochrome bd and
bo and T. vivax AOX
Compounds Cytochrome bda Cytochrome bob trypanosome AOXc
LL-Z1272β 2.1±0.1d 1.2±0.1 0.18±0.02
LL-Z1272γ 81±17 0.082±0.016 0.015±0.001
LL-Z1272δ 32±4 0.28±0.02 0.046±0.004
LL-Z1272ɛ 1.1±0.1 7.2±0.7 0.65±0.09
LL-Z1272ζ 85±7 0.37±0.02 0.43±0.02
Ascofuranone 47±10 0.062±0.003 0.0049±0.0002
Aurachin C 1–10 0.0083±0.0003 0.0023±0.0001 28±2
a The E. coli cytochrome bd-overproduced membranes.
b The puriﬁed E. coli cytochrome bo.
c The T. vivax AOX-overproduced membranes.
d μM.
131T. Mogi et al. / Biochimica et Biophysica Acta 1787 (2009) 129–1333.2. Kinetic analysis of inhibition of cytochrome bd by LL-Z1272β and ɛ
Effects of LL-Z1272β and ɛ on the Q1H2 oxidation by cytochrome bd
were further analyzed kinetically. Control data were analyzed based
on the modiﬁed ping-pong bi-bi mechanism by assuming the
stabilization of dioxygen reduction intermediates [28] and apparent
Km and Vmax values for the control were determined to 50 μM and
2364 Q1H2/enzyme/s, respectively, in 50 mM potassium phosphate
(pH 6.5)–0.02% Tween 20 [24] (Fig. 2). In the presence of inhibitors,
reactions followed the Michaelis–Menten kinetics (Fig. 2). LL-Z1272β
acts as a noncompetitive inhibitor with Ki =7.6±2.5 μM while LL-
Z1272ɛ serves as a competitive inhibitor with Ki =1.00±0.03 μM
(Fig. 2).
3.3. Dose–response analysis of inhibition of cytochrome bo
by antibiotics LL-Z1272
In contrast to bd-type oxidase, the Q1H2 oxidase activity of the E.
coli cytochrome bo was more sensitive to chlorinated derivatives, LL-
Z1272γ, ɛ and ζ. IC50 values for LL-Z1272β, γ, δ, ɛ and ζ (averages from
two preparations) were determined to be 1.2, 0.082, 0.28, 7.2 and
0.37 μM, respectively (Table 1). The IC50 values for known inhibitors
for cytochrome bo [20,27,29–31] are 0.3 μM for HQNO, 0.14 μM for
piericidin A, and 2.3 nM for aurachin C 1–10, showing that cytochromeFig. 2. Effects of antibiotics LL-Z1272 on kinetic parameters for Q1H2 oxidation by the E.
coli cytochrome bd. Kinetic analysis was carried out in the absence of inhibitors (•) and
the presence of 2 (▾) or 5 (▿) μM LL-Z1272β or 2 (▴) or 5 (▵) μM LL-Z1272ɛ. Control
data was analyzed by using the equation v=SVmax / (SS(1+S /KS)+SKm+KmKm) where KS
indicates the constant for substrate inhibition. Data obtained in the presence of
inhibitors were analyzed based on the Michaelis–Menten kinetics. The apparent Km
(μM) and Vmax (Q1H2/enzyme) values obtained were 50±4 and 2364±194, respec-
tively, for the control (KS=381 μM), 79±5 and 1232±33, respectively, for 2 μM LL-
Z1272β, 100±5 and 826±21, respectively, for 5 μM LL-Z1272β, 140±3 and 1065±12,
respectively, for 2 μM LL-Z1272ɛ, 287±41 and 1113±107 Q1H2/enzyme/s, respectively,
for 5 μM LL-Z1272ɛ, respectively.bo is more sensitive to these quinone analogs than cytochrome bd. It
should be noted that LL-Z1272γ is a very potent inhibitor of
cytochrome bo.
3.4. Kinetic analysis of inhibition of cytochrome bo by antibiotics
LL-Z1272
Effects of LL-Z1272β, γ, δ, and ζ on the Q1H2 oxidation by
cytochrome bo were further analyzed kinetically at different concen-
trations of inhibitors. Enzyme kinetics were analyzed based on the
Michaelis–Menten mechanism [29,31], and we found that the
inhibition mechanism was all mixed-type (Fig. 3). It should be noted
that due to changes in assay conditions apparent Km and Vmax values
were shifted to 23 μM and 1035 Q1H2/enzyme/s, respectively (Fig. 3),
from 50 μM and 515 Q1H2/enzyme/s, respectively, in 50 mM Tris–HCl
(pH 7.4)–0.1% sucrose monolaurate in our previous study [32].
3.5. Dose–response analysis of inhibition of trypanosome AOX by
antibiotics LL-Z1272
Because of the structural similarity of antibiotics LL-Z1272 with
trypanocidal AF (Fig. 1), we examined the effects of antibiotics LL-
Z1272 on Q1H2 oxidase activity of T. vivax AOX. From dose–response
analysis with the AOX-overproduced E. coli membranes, we deter-
mined IC50 values for LL-Z1272β, γ, δ, ɛ, ζ, AF and aurachin C1–10 to be
180, 15, 46, 650, 430, 4.9 nM and 28 μM, respectively (Table 1). Our
data indicate that 1) the furanone ring of AF is not essential for binding
to trypanosome AOX, 2) the 5-chloride group on the phenol ring
increases the binding afﬁnity, and 3) aurachin C, the most potent
inhibitor for bacterial quinol oxidases (IC50=8.3 and 2.3 nM for the E.
coli cytochrome bd and bo, respectively (Table 1)) [20,27], is 2 to 4
order of magnitude less active than the prenylphenols.
3.6. Kinetic analysis of inhibition of trypanosome AOX by antibiotics
LL-Z1272
Effects of LL-Z1272β, γ, δ, ɛ and ζ and AF on enzyme kinetics by T.
vivax AOX were examined in the presence of detergents. Q1H2
oxidation by T. vivax AOX followed the Michaelis–Menten kineticsFig. 3. Effects of antibiotics LL-Z1272 on kinetic parameters for Q1H2 oxidation by the E.
coli cytochrome bo. Kinetic analysis was carried out in the absence of inhibitors (○) and
the presence of 0.75 μM LL-Z1272β (▾), 0.2 μM LL-Z1272γ (•), 0.75 μM LL-Z1272δ (▴),
and ζ (▿). Data were analyzed based on the Michaelis–Menten kinetics. The apparent
Km and Vmax values obtained are 23±2 and 1035±28 (control), 43±4 and 841±30
(0.75 μM LL-Z1272β), 64±2 and 402±4 (0.2 μM LL-Z1272γ), 66±3 and 361±6 (0.75 μM
LL-Z1272δ), 46±4 μM and 486±14 Q1H2/enzyme/s (0.75 μM LL-Z1272ζ), respectively. R
values were N0.997.
Fig. 4. Effects of antibiotics LL-Z1272 on kinetic parameters for Q1H2 oxidation by
trypanosome AOX. Kinetic analysis was carried out in the absence of inhibitors (▵) and
the presence of 200 nM LL-Z1272β (▾), 20 nM LL-Z1272γ (•), 50 nM LL-Z1272δ (▴),
1 μM LL-Z1272ɛ (○) and 50 nM LL-Z1272ζ (▿), and 5 nM AF (♦). For clarity we showed
data for one concentration of each inhibitor. The apparent Km and Vmax values
determined for the control were 232 μM and 19.8 U/mg protein, respectively. The
apparent Ki values for non-competitive inhibition by LL-Z1272β, γ, ζ, and AF were 142,
59, 203, and 2.65 nM. Ki and Ki′ values for mixed-type inhibition by LL-Z1272δ and LL-
Z1272ɛ were 0.032 and 25.5 μM and 0.483 and 9.61 μM, respectively.
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20 U/mg protein (Fig. 4). The Km value in 0.1% sucrose monolaurate
was comparable to 350 μM for T. b. brucei AOX in 0.25% n-octyl-β-D-
glucopyranoside plus 0.025% EDT-20 [34], but smaller than approxi-
mately 700 μM determined for T. b. brucei AOX in the absence of
detergents [13,23]. Since the Km value of T. vivax AOX for ubiquinol-2
was 116 μM (data not shown), the length of the isoprene unit may
increase the binding afﬁnity for ubiquinones [35]. The Km of
trypanosome AOX for ubiquinol-9 in T. b. brucei mitochondria
would be comparable to the Km value of cytochrome bd for
ubiquinol-8 in E. coli.
Kinetic analysis of inhibition of T. vivax AOX by antibiotics LL-
Z1272 revealed that LL-Z1272β (Ki =142 nM), γ (59 nM), and ζ
(203 nM) act as (apparently) non-competitive inhibitors (Fig. 4), as
reported for AF [13] and salicylhydroxamic acid (SHAM, Ki =25 μM)
[34]. Since the amount of active AOX molecules in the E. coli
membranes was difﬁcult to estimate, we did not try kinetic analysis
for tight-binding inhibitors [36]. In contrast, LL-Z1272δ and ɛ serve as
mixed-type inhibitors with Ki and Ki′ values of 0.032 and 25.5 μM and
0.483 and 9.61 μM, respectively.
4. Discussion
From the screening of natural antibiotics of the Kitasato Institute
for Life Sciences Chemical Library, we identiﬁed prenylphenols LL-
Z1272β, γ, δ, ɛ and ζ as a unique set of inhibitors, which can inhibit and
discriminate bacterial and trypanosomal ubiquinol oxidases (Table 1).
LL-Z1272β and ɛ (dechlorinated derivatives) inhibited cytochrome bd-
type oxidase while LL-Z1272γ, δ, and ζ (chlorinated derivatives) were
potent inhibitors of cytochrome bo-type oxidase and trypanosome
AOX. Aurachin C is a potent inhibitor for both cytochrome bo and bd
[20,27], while AF is more active against trypanosome AOX [13]. Since
all three quinol oxidases are absent from mammalian mitochondria,
prenylphenols could be used as lead compounds for development of
novel chemotherapeutic agents [13,14,37]. However, except for the
effect of LL-Z1272β on Clostridium perfringens (minimum inhibitory
concentration of 25 μg/ml), antibiotics LL-Z1272 were ineffective
against S. aureus, Pseudomonas aeruginosa, Mycobacterium smegmatis,
and Bacteroides fragilis. Neither LL-Z1272γ nor LL-Z1272ɛ affected theaerobic growth of E. coli cells expressing cytochrome bo or bd as the
sole terminal oxidase, likely due to the excretion by drug efﬂux pumps
or due to the inefﬁcient penetration through the lipopolysaccharide
layer of the outer membrane.
Kinetic analysis of the inhibition of quinol oxidases by prenylphe-
nols yielded rather complicated inhibition mechanisms (Figs. 2–4).
Structural similarities of prenylphenols to ubiquinones (Fig. 1) indi-
cate that all these compounds would act as competitive inhibitors for
the quinol oxidation site. However, in many cases we found non-
competitive or mixed type inhibition. In the case of tight binding
inhibitors [36], Michaelis–Menten plots resemble to those of non-
competitive inhibition. Alternatively, orientation of the phenol ring of
prenylphenol molecules within the binding pocket will determine
interactions of prenyl tails and/or the cyclohexanone ring with the
protein moiety. The latter interactions would affect the former
interactions. In addition, modiﬁcations of the prenyl tail (i.e., the
presence of the cyclohexanone or franone ring) could alter interac-
tions with lipid bilayers and detergent micelles, which would then
affect the orientation of inhibitor molecules relative to the binding
pocket in quinol oxidases. Inhibition mechanisms of natural
antibiotics may be inherently associated with their structural
complexity, as found for inhibitors for alternative NADH dehydro-
genase NDH-II [38].
Currently approved drugs for the treatment of human sleeping
sickness caused by T. b. rhodesiense and T. b. gambiense are suramine,
pentamidine, melarsoprol, and eﬂornithine [37]. They are not
available for oral administration and T. brucei strains resistant to
one or more drugs are now emerging. Thus there is an urgent need
for less-toxic and more convenient new drugs against African
trypanosomiasis. In parallel studies, we recently found trypanocidal
activity of LL-Z1272β [39]. LL-Z1272β and LL-Z1272δ have been
shown to be less toxic to human cells [18,33] and we have
demonstrated that the efﬁcacy of AF in the treatment of trypano-
some-infected mice [14]. In conclusion, antibiotics LL-Z1272 are
useful as probes for understanding the quinol oxidation sites of
respiratory quinol oxidases and such prenylphenols are promising
leading compounds for the development of new chemotherapeutic
agents for African trypanosomiasis.
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AOX: alternatice quinol oxidase
HQNO: 2-heptyl-4-hydroxyquinoline N-oxide
IC50: IC50, the 50% inhibitory concentration
Q1H2: a reduced form of Q1, ubiquinol-1
